Cargando…

Prognostic value of HPV-mRNA in sentinel lymph nodes of cervical cancer patients with pN0-status

Up to 15% of patients with cervical cancer and pN0-status develop recurrent-disease. This may be due to occult metastatic spread of tumor cells. We evaluated the use of human-papillomavirus-(HPV)-mRNA as a molecular marker for disseminated tumor cells to predict the risk of recurrence. For this pros...

Descripción completa

Detalles Bibliográficos
Autores principales: Dürst, Matthias, Hoyer, Heike, Altgassen, Christoph, Greinke, Christiane, Häfner, Norman, Fishta, Alba, Gajda, Mieczyslaw, Mahnert, Ute, Hillemanns, Peter, Dimpfl, Thomas, Lenhard, Miriam, Petry, K. Ulrich, Runnebaum, Ingo B., Schneider, Achim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673218/
https://www.ncbi.nlm.nih.gov/pubmed/26008982
_version_ 1782404693059698688
author Dürst, Matthias
Hoyer, Heike
Altgassen, Christoph
Greinke, Christiane
Häfner, Norman
Fishta, Alba
Gajda, Mieczyslaw
Mahnert, Ute
Hillemanns, Peter
Dimpfl, Thomas
Lenhard, Miriam
Petry, K. Ulrich
Runnebaum, Ingo B.
Schneider, Achim
author_facet Dürst, Matthias
Hoyer, Heike
Altgassen, Christoph
Greinke, Christiane
Häfner, Norman
Fishta, Alba
Gajda, Mieczyslaw
Mahnert, Ute
Hillemanns, Peter
Dimpfl, Thomas
Lenhard, Miriam
Petry, K. Ulrich
Runnebaum, Ingo B.
Schneider, Achim
author_sort Dürst, Matthias
collection PubMed
description Up to 15% of patients with cervical cancer and pN0-status develop recurrent-disease. This may be due to occult metastatic spread of tumor cells. We evaluated the use of human-papillomavirus-(HPV)-mRNA as a molecular marker for disseminated tumor cells to predict the risk of recurrence. For this prospective, multi-center prognostic study, 189 patients free of lymphnode metastases by conventional histopathology could be analyzed. All patients underwent complete lymphadenectomy. Of each sentinel node (SLN) a biopsy was taken for the detection of HPV-E6-E7-mRNA. Median follow-up time after surgery was 8.1 years. HPV-mRNA could be detected in SLN of 52 patients (27.5%). Recurrence was observed in 22 patients. Recurrence-free-survival was significantly longer for patients with HPV-negative SLN (log rank p = 0.002). By Cox regression analysis the hazard ratio (95%CI) for disease-recurrence was 3.8 (1.5 – 9.3, p = 0.004) for HPV-mRNA-positive compared to HPV-mRNA-negative patients. After adjustment for tumor size as the most influential covariate the HR was still 2.8 (1.1 – 7.0, p = 0.030). In patients with cervical cancer and tumor-free lymph nodes by conventional histopathology HPV-mRNA-positive SLN were of prognostic value independent of tumor size. Particularly, patients with tumors larger than 20mm diameter could possibly benefit from further risk stratification using HPV-mRNA as a molecular marker.
format Online
Article
Text
id pubmed-4673218
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-46732182015-12-23 Prognostic value of HPV-mRNA in sentinel lymph nodes of cervical cancer patients with pN0-status Dürst, Matthias Hoyer, Heike Altgassen, Christoph Greinke, Christiane Häfner, Norman Fishta, Alba Gajda, Mieczyslaw Mahnert, Ute Hillemanns, Peter Dimpfl, Thomas Lenhard, Miriam Petry, K. Ulrich Runnebaum, Ingo B. Schneider, Achim Oncotarget Clinical Research Paper Up to 15% of patients with cervical cancer and pN0-status develop recurrent-disease. This may be due to occult metastatic spread of tumor cells. We evaluated the use of human-papillomavirus-(HPV)-mRNA as a molecular marker for disseminated tumor cells to predict the risk of recurrence. For this prospective, multi-center prognostic study, 189 patients free of lymphnode metastases by conventional histopathology could be analyzed. All patients underwent complete lymphadenectomy. Of each sentinel node (SLN) a biopsy was taken for the detection of HPV-E6-E7-mRNA. Median follow-up time after surgery was 8.1 years. HPV-mRNA could be detected in SLN of 52 patients (27.5%). Recurrence was observed in 22 patients. Recurrence-free-survival was significantly longer for patients with HPV-negative SLN (log rank p = 0.002). By Cox regression analysis the hazard ratio (95%CI) for disease-recurrence was 3.8 (1.5 – 9.3, p = 0.004) for HPV-mRNA-positive compared to HPV-mRNA-negative patients. After adjustment for tumor size as the most influential covariate the HR was still 2.8 (1.1 – 7.0, p = 0.030). In patients with cervical cancer and tumor-free lymph nodes by conventional histopathology HPV-mRNA-positive SLN were of prognostic value independent of tumor size. Particularly, patients with tumors larger than 20mm diameter could possibly benefit from further risk stratification using HPV-mRNA as a molecular marker. Impact Journals LLC 2015-05-14 /pmc/articles/PMC4673218/ /pubmed/26008982 Text en Copyright: © 2015 Dürst et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Clinical Research Paper
Dürst, Matthias
Hoyer, Heike
Altgassen, Christoph
Greinke, Christiane
Häfner, Norman
Fishta, Alba
Gajda, Mieczyslaw
Mahnert, Ute
Hillemanns, Peter
Dimpfl, Thomas
Lenhard, Miriam
Petry, K. Ulrich
Runnebaum, Ingo B.
Schneider, Achim
Prognostic value of HPV-mRNA in sentinel lymph nodes of cervical cancer patients with pN0-status
title Prognostic value of HPV-mRNA in sentinel lymph nodes of cervical cancer patients with pN0-status
title_full Prognostic value of HPV-mRNA in sentinel lymph nodes of cervical cancer patients with pN0-status
title_fullStr Prognostic value of HPV-mRNA in sentinel lymph nodes of cervical cancer patients with pN0-status
title_full_unstemmed Prognostic value of HPV-mRNA in sentinel lymph nodes of cervical cancer patients with pN0-status
title_short Prognostic value of HPV-mRNA in sentinel lymph nodes of cervical cancer patients with pN0-status
title_sort prognostic value of hpv-mrna in sentinel lymph nodes of cervical cancer patients with pn0-status
topic Clinical Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673218/
https://www.ncbi.nlm.nih.gov/pubmed/26008982
work_keys_str_mv AT durstmatthias prognosticvalueofhpvmrnainsentinellymphnodesofcervicalcancerpatientswithpn0status
AT hoyerheike prognosticvalueofhpvmrnainsentinellymphnodesofcervicalcancerpatientswithpn0status
AT altgassenchristoph prognosticvalueofhpvmrnainsentinellymphnodesofcervicalcancerpatientswithpn0status
AT greinkechristiane prognosticvalueofhpvmrnainsentinellymphnodesofcervicalcancerpatientswithpn0status
AT hafnernorman prognosticvalueofhpvmrnainsentinellymphnodesofcervicalcancerpatientswithpn0status
AT fishtaalba prognosticvalueofhpvmrnainsentinellymphnodesofcervicalcancerpatientswithpn0status
AT gajdamieczyslaw prognosticvalueofhpvmrnainsentinellymphnodesofcervicalcancerpatientswithpn0status
AT mahnertute prognosticvalueofhpvmrnainsentinellymphnodesofcervicalcancerpatientswithpn0status
AT hillemannspeter prognosticvalueofhpvmrnainsentinellymphnodesofcervicalcancerpatientswithpn0status
AT dimpflthomas prognosticvalueofhpvmrnainsentinellymphnodesofcervicalcancerpatientswithpn0status
AT lenhardmiriam prognosticvalueofhpvmrnainsentinellymphnodesofcervicalcancerpatientswithpn0status
AT petrykulrich prognosticvalueofhpvmrnainsentinellymphnodesofcervicalcancerpatientswithpn0status
AT runnebaumingob prognosticvalueofhpvmrnainsentinellymphnodesofcervicalcancerpatientswithpn0status
AT schneiderachim prognosticvalueofhpvmrnainsentinellymphnodesofcervicalcancerpatientswithpn0status